

SAH
#11/2
7-10-02
PATENT

jc872 U.S. PRO
10/014389
10/22/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	HAEMOSYS GMBH et al.
Serial No.:	To Be Assigned 10/014389
Filed:	Herewith 10-22-01
For:	PROCESS FOR THE DIAGNOSIS OF DISEASES, PATHOLOGICAL STATES AND PATHOPHYSIOLOGICAL MEASUREMENT UNITS
Docket No.:	VOS0003/US

Commissioner for Patents
Washington, DC 20231

EXPRESS MAIL LABEL NO. EL789926237USS

I CERTIFY THAT, ON OCTOBER 22, 2001, THIS PAPER IS BEING
DEPOSITED WITH THE U.S. POSTAL SERVICE AS EXPRESS MAIL POST
OFFICE TO ADDRESSEE SERVIE UNDER 37 C.F.R. 1.10 IN AN ENVELOPE
ADDRESSED TO COMMISSIONER FOR PATENTS, WASHINGTON, D.C.
20231.

Barbara A. Avery
Barbara A. Avery

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure imposed by 37 C.F.R. § 1.56 and in accordance with the provisions of 37 C.F.R. §§ 1.97, 1.98 and the Manual of Patent Examining Procedure 609, Applicants bring to the attention of the Examiner the following information. The Examiner's independent and thorough review of this information is solicited.

Attached hereto please find Form PTO-1449 listing the cited references. Copies of the cited references are also enclosed. The Examiner is requested to indicate consideration of each reference by initialing in the appropriate box for each reference, and returning an initialed copy with the next official action.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.56 to bring to the Examiner's attention those references which may be material to the Examiner for examination of this case. However, the citation of the above references in this Information Disclosure Statement is not intended to constitute an admission that any patent or other reference referred to herein is "prior art" for this invention. In this regard, Applicants expressly reserve the right to contest that any of the references constitute "prior art."

Page 2
October 22, 2001

Also enclosed is a copy of the PCT International Search Report of the PCT priority document of this application.

No fee is believed to be necessary for the consideration of this Information Disclosure Statement since it is being filed within three months of the filing date or before the receipt of an Office Action on the merits. However, if a fee is required, please charge our Deposit Account No. 50-1775 and notify us of the same.

Respectfully Submitted,

By:

Dale A. Bjorkman, Reg. No. 33,084
KAGAN BINDER, PLLC
Suite 200 Maple Island Building
221 Main Street North
Stillwater, Minnesota 55082
651-275-9811

DAB/1806